Epsilogen Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 14

Epsilogen General Information

Description

Operator of an antibody therapeutics platform intended to develop novel immunotherapy treatments for cancer. The company offers immunoglobulin-based therapeutic antibodies targeting cancer-associated biomarkers and immune pathways, enabling oncology patients and healthcare providers to access targeted treatments that support improved anti-tumor immune responses and disease management.

Contact Information

Website
www.epsilogen.com
Formerly Known As
IGEM Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Waterfront, ARC West London
  • Manbre Road, Hammersmith
  • London W6 9RH
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Waterfront, ARC West London
  • Manbre Road, Hammersmith
  • London W6 9RH
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epsilogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B) 09-Sep-2024 Completed Clinical Trials - Phase 1
6. Grant 21-Oct-2020 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A2) 16-Jul-2020 Completed Clinical Trials - Phase 1
4. Grant 02-Apr-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A1) 19-Nov-2018 Completed Clinical Trials - Phase 1
2. Grant 09-May-2018 $2.02M Completed Clinical Trials - Phase 1
1. University Spin-Out 26-Jul-2016 Completed Startup
To view Epsilogen’s complete valuation and funding history, request access »

Epsilogen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series B
Series A2 5,545,454 $0.000131 $0.72 $0.72 1x $0.72 7.24%
Series A 10,000,000 $0.000131 $0.65 $0.65 1x $0.65 13.05%
To view Epsilogen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Epsilogen Patents

  • 47

    Total Documents Applications and Grants

  • Total Patents Families

  • 17

    Granted

  • 18

    Pending

  • Expiring in next 12 mo

Epsilogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026185419-A1 Engineered iga anti-epithelial cell adhesion molecule Pending 05-Mar-2025
WO-2026132382-A3 Anti-her2 ige antibody for use in cancer treatment Pending 20-Dec-2024
GB-202418843-D0 Composition Inactive 20-Dec-2024
WO-2026132382-A2 Composition Pending 20-Dec-2024
GB-202418863-D0 Heteromultimeric proteins Pending 20-Dec-2024
To view Epsilogen’s complete patent history, request access »

Epsilogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epsilogen Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
3B Future Health Fund Venture Capital Minority
British Business Bank Lender/Debt Provider Minority
Global BioAccess Fund Venture Capital Minority
Novartis Venture Fund Corporate Venture Capital Minority
Schroders Capital Asset Manager Minority
You’re viewing 5 of 14 investors. Get the full list »

Epsilogen Acquisitions (1)

Epsilogen’s most recent deal was a Merger/Acquisition with TigaTx. The deal was made on 13-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TigaTx 13-Mar-2025 Merger/Acquisition Drug Discovery
To view Epsilogen’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Epsilogen Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
TigaTx Boston, MA 2018

Epsilogen FAQs

  • When was Epsilogen founded?

    Epsilogen was founded in 2016.

  • Where is Epsilogen headquartered?

    Epsilogen is headquartered in London, United Kingdom.

  • What is the size of Epsilogen?

    Epsilogen has 24 total employees.

  • What industry is Epsilogen in?

    Epsilogen’s primary industry is Drug Discovery.

  • Is Epsilogen a private or public company?

    Epsilogen is a Private company.

  • What is Epsilogen’s current revenue?

    The current revenue for Epsilogen is .

  • How much funding has Epsilogen raised over time?

    Epsilogen has raised $66.7M.

  • Who are Epsilogen’s investors?

    3B Future Health Fund, British Business Bank, Global BioAccess Fund, Novartis Venture Fund, and Schroders Capital are 5 of 14 investors who have invested in Epsilogen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process